Skip to main content

Advertisement

Log in

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

  • Original article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

CD40 is a member of the TNF family of receptors that has been shown to play a crucial role in enhancing dendritic cell activity and fostering anti-tumor immune responses. In this study, we demonstrate the in vitro properties and in vivo efficacious activity of the CD40 agonist antibody, CP-870,893. CP-870,893 is a fully human, IgG2 antibody that selectively interacts with CD40 at a site distinct from its ligand-binding region with a KD of 0.4 nM. It enhances the expression of MHC class II, CD54, CD86, and CD23 on human B cells in vitro. CP-870,893 also enhances dendritic cell activity as evidenced by cytokine secretion (IL-12, IL-23, IL-8), the upregulation of CD86 and CD83, and the ability to prime T cells to secrete IFNγ. In SCID-beige mice, a single parenteral injection of CP-870,893 was therapeutically effective against several CD40pos human tumors (B-cell lymphoma, breast, colon, and prostate) indicating direct effects on tumor cell survival and/or growth. When mice were co-implanted with human T cells and dendritic cells, the activity of CP-870,893 against CD40pos tumors increased, and efficacy was also observed against CD40neg and CD40low tumors demonstrating the ability of CP-870,893 to enhance anti-tumor immune function in vivo. These studies suggest that CP-870,893 has the potential to be efficacious against a wide range of tumor types through both direct and immune-mediated effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chaudhuri D, Suriano R, Mittelman A, Tiwari RK (2009) Targeting the immune system in cancer. Curr Pharm Biotechnol 10:166–184

    Article  PubMed  CAS  Google Scholar 

  2. Lustgarten J (2009) Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 58:1979–1989

    Google Scholar 

  3. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152–172

    Article  PubMed  CAS  Google Scholar 

  4. Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE (2000) The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med 78:363–371

    Article  PubMed  CAS  Google Scholar 

  5. Sartorius R, D’Apice L, Barba P et al (2003) Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells. Cell Immunol 221:81–88

    Article  PubMed  CAS  Google Scholar 

  6. Davis ID, Chen Q, Morris L et al (2006) Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother 29:499–511

    Article  PubMed  Google Scholar 

  7. Mackey MF, Gunn JR, Ting PP et al (1997) Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 57:2569–2574

    PubMed  CAS  Google Scholar 

  8. Hanyu K, Iida T, Shiba H, Ohashi T, Eto Y, Yanaga K (2008) Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats. Anticancer Res 28:2785–2789

    PubMed  Google Scholar 

  9. Dzojic H, Loskog A, Totterman TH, Essand M (2006) Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66:831–838

    Article  PubMed  CAS  Google Scholar 

  10. French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T cell help. Nat Med 5:548–553

    Article  PubMed  CAS  Google Scholar 

  11. French RR, Taraban VY, Crowther GR et al (2007) Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109:4810–4815

    Article  PubMed  CAS  Google Scholar 

  12. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM (2003) Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T cell-dependent immunity–B cell lymphoma. Blood 102:1449–1457

    Article  PubMed  CAS  Google Scholar 

  13. Tutt AL, O’Brien L, Hussain A, Crowther GR, French RR, Glennie MJ (2002) T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168:2720–2728

    PubMed  CAS  Google Scholar 

  14. Todryk SM, Tutt AL, Green MH et al (2001) CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 248:139–147

    Article  PubMed  CAS  Google Scholar 

  15. van Mierlo GJ, den Boer AT, Medema JP et al (2002) CD40 stimulation leads to effective therapy of CD40(−) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 99:5561–5566

    Article  PubMed  Google Scholar 

  16. Diehl L, den Boer AT, Schoenberger SP et al (1999) CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5:774–779

    Article  PubMed  CAS  Google Scholar 

  17. Vonderheide RH, Dutcher JP, Anderson JE et al (2001) Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19:3280–3287

    PubMed  CAS  Google Scholar 

  18. Toes RE, Schoenberger SP, van der Voort EI, Offringa R, Melief CJ (1998) CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol 10:443–448

    Article  PubMed  CAS  Google Scholar 

  19. Hirano A, Longo DL, Taub DD et al (1999) Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93:2999–3007

    PubMed  CAS  Google Scholar 

  20. Hill SC, Youde SJ, Man S et al (2005) Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 174:41–50

    PubMed  CAS  Google Scholar 

  21. Gomes EM, Rodrigues MS, Phadke AP et al (2009) Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 15:1317–1325

    Article  PubMed  CAS  Google Scholar 

  22. Georgopoulos NT, Merrick A, Scott N, Selby PJ, Melcher A, Trejdosiewicz LK (2007) CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Cancer 121:1373–1381

    Article  PubMed  CAS  Google Scholar 

  23. Vonderheide RH, Butler MO, Liu JF et al (2001) CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/86 expression or T cell alloreactivity. Int J Oncol 19:791–798

    PubMed  CAS  Google Scholar 

  24. Frucht DM (2002) IL-23: a cytokine that acts on memory T cells. Sci STKE 114:1–3

    Google Scholar 

  25. Tahara H, Lotze MT (1995) Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 2:96–106

    PubMed  CAS  Google Scholar 

  26. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359–3365

    PubMed  CAS  Google Scholar 

  27. Weerasekera N, Hudson I (2007) Lessons from TGN-1412: the impact on phase I clinical trials. IDrugs 10:230–232

    PubMed  Google Scholar 

  28. Biancone L, Cantaluppi V, Boccellino M et al (1999) Activation of CD40 favors the growth and vascularization of Kaposi’s sarcoma. J Immunol 163:6201–6208

    PubMed  CAS  Google Scholar 

  29. Vonderheide RH, Flaherty KT, Khalil M et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876–883

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ronald P. Gladue.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gladue, R.P., Paradis, T., Cole, S.H. et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother 60, 1009–1017 (2011). https://doi.org/10.1007/s00262-011-1014-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-011-1014-6

Keywords

Navigation